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Abstract: 
• Chronic kidney disease stages 1 to 4 are asymptomatic health states that 
are not “disease” according to previously proposed definitions of disease.  
• Reduced kidney function levels, currently called chronic kidney disease, 
are not abnormal in older age groups.  
• The label “chronic kidney disease” can be misinterpreted by patients and 
can be an obstacle to communication.  
• Relabelling the stages of “chronic kidney disease” as categories of 
“kidney age” could improve patient-doctor communication and patient 
understanding of their diagnosis.  
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Key points 
• Chronic kidney disease stages 1 to 4 are asymptomatic health states that are not “disease” 
according to previously proposed definitions of disease. 
• Reduced kidney function levels, currently called chronic kidney disease, are not abnormal in 
older age groups. 
• The label “chronic kidney disease” can be misinterpreted by patients and can be an obstacle 
to communication. 
• Relabelling the stages of “chronic kidney disease” as categories of “kidney age” could 
improve patient-doctor communication and patient understanding of their diagnosis. 
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Introduction  
While a variety of conditions and syndromes may affect the kidneys over either chronic or acute 
time frames, the term “chronic kidney disease” (CKD) is used to describe a decrease in the filtration 
ability of the glomerular capillaries in the kidney.  The most prevalent forms of CKD in healthcare 
systems are typically the asymptomatic stages conventionally termed CKD stage 4 or below (1)I(2).  
Should these asymptomatic stages be called “disease”?   
What is meant by “chronic kidney disease”? 
In 2002 the US National Kidney Foundation proposed that the term  “chronic kidney disease” (CKD) 
be applied for specific dysfunctions of the kidneys, defined primarily by the glomerular filtration rate 
(GFR).  These guidelines proposed that GFR below 60 ml/min/1.73m
2
 be considered CKD stage 3; 
GFR below 30 ml/min/1.73m
2
, CKD stage 4;  and below 15 ml/min/1.73m
2
, CKD
 
stage 5, with earlier 
stages (1 and 2) dependent on other evidence of kidney damage such as proteinuria (3).  This 
approach has proved popular, arguably because it can be linked to clear clinical action plans (4).  
Subsequent guidelines in Canada, the UK and elsewhere, as well as the US, have updated this 
scheme or proposed modifications for other countries (5).  These revisions have often subdivided 
stage 3 with an additional threshold at 45 ml/min/1.73m
2
 and/or introduced a secondary 
classification by proteins in urine, but the emphasis on GFR, often estimated using markers in the 
blood, has remained constant.   
High-quality observational evidence shows a relationship between the stages of CKD and 
cardiovascular disease as well as end-stage renal disease.  A meta-analysis of large cohort studies 
shows that cardiovascular risk increases with each level of GFR in Table 1, as does risk of future ESRD 
and risk of acute kidney injury (4,6).  These risks also increase with albuminuria, at all levels of GFR 
except below 15 ml/min/1.75m
2
 (stage 5).  It has been argued that the utility of CKD classification is 
that it can be linked to a clear action plan (4), although the level of evidence for most of the 
recommended interventions is not strong (7).   
What constitutes a disease? 
Smart (8) reviewed four prominent definitions of disease in the philosophy of medicine literature.  
We considered whether CKD, defined by current thresholds for GFR, is disease by these 
definitions(9). We found that CKD stage 5 was disease by any definition, because it is associated with 
harm and statistically rare in any age group.  However, earlier stages of CKD are associated with 
harm as risk factors for further disease (renal or cardiovascular) rather than as disease itself, and 
whether they are statistically abnormal depends entirely on age(6). 
Is the label ‘chronic kidney disease’ helpful to patients or 
clinicians?  
Qualitative data from both clinicians (10,11) and patients (12) have demonstrated that 
communicating a diagnosis of ‘CKD’ to patients can be  uncomfortable and unsatisfactory for all 
concerned. As soon as the words ‘chronic’ or ‘disease’ are introduced within a consultation, primary 
care physicians face an uphill battle to retrieve the situation with reassurance (13). Our research (14) 
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found that the word ‘chronic’ is often misinterpreted by patients as meaning serious, and ‘kidney 
disease’ can trigger thoughts of dialysis and transplant because people are usually unaware that 
earlier stages of kidney impairment exist before treatment becomes necessary (see Box 1 quotes 1 & 
2).  
Clinicians may avoid using the term CKD with their patients or disclosing the diagnosis altogether. 
Daker-White et al (12) found that 19 of 26 CKD patients interviewed in their study had been told 
something about their kidney function but only four had been explicitly given a diagnosis of CKD. A 
study of clinician views found a concern amongst GPs about possibly alarming patients by giving 
them a disease label when their kidney function was only mildly impaired (11). However, in our 
study and Daker-White’s (12), non-disclosure of a CKD diagnosis led to some patients finding out 
about it by accident, such as when consulting a different clinician to usual who assumed they already 
knew. Such accidental disclosure could lead to shock, anger and upset (see Box 1 quote 3). 
Blakeman et al (13) found GPs in their study felt a need to underplay CKD when discussing it with 
patients. Patient participants in Daker-White’s and our research reported having their kidney 
function described by doctors in euphemisms such as ‘borderline’, ‘under par’ or ‘leaking kidneys’, 
rather than as a chronic disease (14).  
Regardless of the terms used by professionals to describe early stage CKD to their patients, where it 
is disclosed it is accompanied by efforts at reassurance that it is nothing to worry about (13). In our 
research (14), being told not to worry without an accompanying explanation or acknowledgement of 
patients’ knowledge of other people with severe kidney failure, often failed to provide sufficient 
reassurance to patients. They were left wanting more information about what might have caused 
their kidney impairment, the severity of it and what the test results meant, was it reversible and how 
quickly might it decline to a level where treatment would be needed, what kind of symptoms they 
should look out for and whether they could do anything to prevent further decline (see Box 1 quote 
4). 
However, where an explanation was offered patients felt more reassured. Knowing that their 
kidneys were still functioning sufficiently to not cause them any problems, that they were being 
regularly monitored and that their test results were satisfactory or stable, were all sources of 
reassurance, as well as the trust they had in their doctor. Many GPs regard reduced but stable 
kidney function in elderly patients as a natural result of ageing, and often use this as the basis for the 
explanation and reassurance they give their patients (11,13). Increasing age was the most common 
explanation for kidney impairment offered to our patient participants, and in most cases was 
successful in providing reassurance that they need not worry about it (see Box 1 quote 5). 
Is “normal” dependent on age? 
An age-related understanding of declining GFR is supported by observational data.  Population-
based studies consistently show that prevalence of CKD depends strongly on age (15). For example, 
prevalence increases approximately ten-fold between young adulthood and middle-age in the US 
Kidney Early Evaluation Program (16) and continues to increase into old age (17).  In the Third (US) 
National Health and Nutrition Survey (NHANES III), Coresh et al. plotted estimated GFR against age 
(18).  The median, and the 5
th
 and 95
th
 centiles declined continuously with age across participants 
from age 20 to age 90 years.   
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Kidney age, not kidney disease? 
These observations suggest that declining kidney function could better be communicated to patients 
in the language of “kidney age” rather than “chronic kidney disease”.  Similar terminology has been 
used previously to communicate current health or health risk to patients.  Spiegelhalter has 
previously reviewed concepts of “heart age”, “brain age” and “lung age” that are based on risk of 
future disease (19).  Groenewegen, in a review of proposed “heart age” and “vascular age” metrics, 
distinguished those based on multivariate prediction of future risk from those based on a single 
current indicator of vascular health such as carotid intima media thickness (CIMT) (20).  In the latter 
approach, the vascular age of an individual with a given CIMT value is the age at which the median 
CIMT in a healthy population is this value.   
 We re-plotted the graphs of Coresh et al., using data from the most recent (2015-6) NHANES survey 
(Figure 1), reversing the axes to propose a mapping from GFR as an indicator of renal health to age 
bands.  CKD stage 3A for example could be communicated as “kidney age 68 to 77 years”, and stage 
3B as “kidney age 77 to 86 years”.  The term “chronic kidney disease” would be reserved for those 
with later stages: in particular, stage 5, or symptomatic stage 4. 
Previous authors have argued that failure to account for age in the definition of CKD stages is a 
“paradox” that accounts for “persistent and serious criticism” of successive CKD classification 
systems (21).  Rather than add complexity to definitions, we hypothesize that adjusting terminology 
would in many cases avoid unnecessary anxiety, while still signalling concern where appropriate.  
When estimated “kidney age” is approximately concordant with calendar age, we hope that patients 
will (as some already do) understand the decline as a natural ageing process.  Conversely, when 
“kidney age” is in excess of calendar age, this should be communicated to patients with discussion 
about increased risk of future cardiovascular and renal disease.   In either case we hypothesize that 
the language of “kidney age” will avoid misunderstandings that arise from the jargon of “chronic” 
kidney “disease”.   
We argue that the earlier stages (up to stage 4) of “chronic kidney disease” are better described as 
kidney ageing, but not that there is no such thing as kidney disease.  Many pathologies affect the 
kidney and have existing nomenclature (nephrotic syndrome; polycystic kidneys; etc) beyond the 
scope of our argument.  Proteinuria can occur even with high GFR, and so a normal or low kidney 
age does not preclude the need to investigate urine protein when indicated (for example, by 
diabetes or hypertension).  Conversely, a decreased GFR, communicated as “increasing kidney age”, 
remains an indication for further investigation and monitoring; and “kidney age” should be taken 
into account in management and prescribing decisions.   
Next steps 
Our proposal is only for a change in terminology, to overcome existing problems with describing 
declining GFR as 'disease'.  The limitations of existing methods for estimating GFR from serum 
creatinine apply equally whether the results are communicated to patients as “CKD stage” or 
“kidney age”. The latter however is likely to have greater resonance with patients, as has the similar 
concept of 'heart or vascular age’.  Usefully, existing clinical and prescribing guidelines, clinical action 
plans and approaches to managing cardiovascular risk would remain unchanged.   
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In our analysis of previous studies, we have used data from a North American study for convenience; 
consideration should be given to whether kidney age should be defined separately in different 
populations: for example, in different ethnic groups. Given a candidate definition of kidney age, 
further work is then merited to test our hypothesis that this concept has advantages over existing 
terminology.  Interviews or focus groups with patients and health care providers, should investigate 
the face validity and acceptability of the “kidney age” concept, and explore other alternatives: “age-
related” or “age-associated” kidney “dysfunction” or “decline”, for example.  If results are 
encouraging then intervention studies could study the change in terminology as an intervention to 
improve patient-doctor communication in the first instance, and patient understanding as a 
consequence.  Some hoped-for consequences might be demonstrable on a large scale: for example, 
an increase in awareness among the proportion of patients on registers (such as the UK CKD 
register).    
The required change in language would need to be widespread, ideally reaching clinical guidelines 
(and software) as well as information materials for the public and for patients, but it would be 
minor, in that it does not in principle require changes to practice, or to the content (as opposed to 
the language) of clinical guidelines.   Potential advantages include: better understanding in those 
with impaired but age-appropriate kidney function; similarly, readier understanding in those with 
age-inappropriate kidney function; hence, greater readiness of family clinicians to discuss declining 
GFR with both groups; avoidance of confusion or distress arising from the jargon term “chronic”; 
reservation of the “disease” for the stages of kidney dysfunction that are associated with direct 
harms – and for which treatment exists.  Although these are consistent with the qualitative research 
findings discussed above, we list them as a potential, rather than proven, advantage, and hope for 
further development and testing of the kidney age concept in the near future. 
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Table 1.  Definitions of chronic kidney disease according to glomerular filtration rate (GFR) by the Kidney Disease Outcome 
Quality Initiative (KDOQI) of the  US National Kidney Foundation. 
Stage Description GFR (mL/min/1.73m
2
) 
1 Kidney damage with normal or 
elevated GFR 
≥90 
2 Kidney damage with mild 
decrease in GFR 
60-89 
3* Moderate decrease in GFR 30-59 
4 Severe decrease in GFR 15-29 
5 Kidney failure <15 (or dialysis) 
* Modified in 2014 to distinguish stage 3a, defined by GFR between 45 and 59 mL/min/1.73m
2
, from 
stage 3b, defined by GFR between 30 and 44 mL/min/1.73m
2
.   
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Figure 1. Percentiles of age by (estimated) GFR (mL/min/1.73m
2
).  National Health and Nutrition Examination Survey 2015 
to 2016.  Red line denotes average (median) age for a given GFR and blue lines denote 5
th
 and 95
th
 centiles. 
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Box 1. Patient quotes (all from our own research (12)  
 
Quote 1 
I couldn’t understand how I could be described as having chronic kidney disease when it had only just been 
discovered. ‘Chronic’ to me means – well maybe mistakenly – that I’ve had it for a long long time … they keep 
using this word ‘chronic’ and I think the word ‘chronic’ makes it sound worse than what it is, to me anyhow. 
(Eric, aged 79)  
Quote 2 
One of my older brothers – he had kidney problems when he was quite young. And then he had kidney failure 
completely and he had a transplant done and that worries me a little bit…  we're both exactly the same build 
and everything. He had bowel cancer and it seems to me everything he got, I get. (Bill, aged 71)  
Quote 3 
I went for my normal routine check up to have blood tests and blood pressure and water and that. And my 
diabetic nurse came in with the nurse that was doing the test to send away to have the results come back and 
she asked me if I’d like to join this programme that you’re running. And I asked her what it was about and she 
explained in my language that it was due to kidney problems. And I went into defensive mode. I said, “No, I’ve 
never had kidney problems. I haven’t got kidney problems with diabetes. It’s you know, I’ve been told 
everything was all right.” And then she told me that I had a kidney problem that was being monitored regularly 
and I asked her, “How long have I had it? Can you tell me when it was diagnosed?” And she said in 1997, which 
was an absolute shock. [laughs] We had a short discussion because she had to go and see to other patients and 
she was under the impression I knew. But my daughter and I had been to the doctors when the results came 
through before, and I’d asked about kidneys and they’d always said, “No, they’re fine.” So this really was a bit 
of a… a shock. I laughed about it at first. I thought that it was a bit of a mix up. But now I understand there isn’t 
but yet I haven’t had it explained to me quite what it entails or what it’s about. (Joan, aged 70) 
Quote 4 
I want to know why they're failing, that’s what I want to know. I mean I'm not a drinker, I don’t drink, so 
whether it is the medication or whether old age,  well, she hasn’t explained. She just, as I say, she [general 
practitioner] has just said that my kidneys aren’t working as they should and I'm almost living on one kidney, 
but I wasn’t to worry because hundreds of people live on one kidney. But then it starts alarm bells ringing 
doesn’t it? Why are your kidneys failing; what have I done to make them fail? Is it my lifestyle, is it tablets? I 
mean it can't be drink because I don’t drink; is it coffee? You don’t know, do you?  
(Elizabeth, aged 74) 
Quote 5 
But as far as an explanation of why the kidneys aren't working perfectly, she [the GP] did, most recently, tell me 
that kidney function decreases as you get older, and I accept that as being the case like everything else. You get 
older you lose your memory and things. (Eric, aged 79) 
 
Page 11 of 12
For Peer Review Only
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential
Table 1.  Definitions of chronic kidney disease according to glomerular filtration rate (GFR) by the Kidney Disease Outcome 
Quality Initiative (KDOQI) of the  US National Kidney Foundation. 
Stage Description GFR (mL/min/1.73m
2
) 
1 Kidney damage with normal or 
elevated GFR 
≥90 
2 Kidney damage with mild 
decrease in GFR 
60-89 
3* Moderate decrease in GFR 30-59 
4 Severe decrease in GFR 15-29 
5 Kidney failure <15 (or dialysis) 
* Modified in 2014 to distinguish stage 3a, defined by GFR between 45 and 59 mL/min/1.73m
2
, from 
stage 3b, defined by GFR between 30 and 44 mL/min/1.73m
2
.   
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Percentiles of age by (estimated) GFR (mL/min/1.73m2).  National Health and Nutrition Examination Survey 
2015 to 2016.  Red line denotes average (median) age for a given GFR and blue lines denote 5th and 95th 
centiles.  
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